26,279 Shares in Harmony Biosciences Holdings, Inc. $HRMY Purchased by Paradiem LLC

Paradiem LLC purchased a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) during the third quarter, HoldingsChannel.com reports. The firm purchased 26,279 shares of the company’s stock, valued at approximately $724,000.

Other large investors have also recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust increased its holdings in shares of Harmony Biosciences by 4,185.2% during the second quarter. Parkside Financial Bank & Trust now owns 1,157 shares of the company’s stock worth $37,000 after buying an additional 1,130 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Harmony Biosciences by 15.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,218 shares of the company’s stock worth $70,000 after acquiring an additional 299 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Harmony Biosciences by 338.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,511 shares of the company’s stock worth $111,000 after acquiring an additional 2,711 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new stake in Harmony Biosciences during the 2nd quarter valued at $120,000. Finally, Ameritas Investment Partners Inc. increased its holdings in Harmony Biosciences by 12.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,466 shares of the company’s stock valued at $141,000 after purchasing an additional 479 shares in the last quarter. 86.23% of the stock is owned by institutional investors.

Harmony Biosciences Trading Down 0.9%

Shares of HRMY opened at $38.13 on Friday. The stock’s fifty day simple moving average is $34.38 and its 200-day simple moving average is $33.52. The firm has a market capitalization of $2.20 billion, a PE ratio of 11.99, a price-to-earnings-growth ratio of 0.48 and a beta of 0.80. Harmony Biosciences Holdings, Inc. has a 12-month low of $25.52 and a 12-month high of $40.93. The company has a quick ratio of 3.72, a current ratio of 3.75 and a debt-to-equity ratio of 0.18.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.87 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.05). Harmony Biosciences had a return on equity of 24.88% and a net margin of 22.50%.The firm had revenue of $239.46 million during the quarter, compared to analyst estimates of $222.68 million. As a group, research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Insider Activity at Harmony Biosciences

In related news, CEO Jeffrey M. Dayno sold 25,933 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $40.11, for a total transaction of $1,040,172.63. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 23.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Weiss Ratings reissued a “hold (c)” rating on shares of Harmony Biosciences in a research note on Monday, December 22nd. Mizuho lifted their price target on Harmony Biosciences from $39.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, December 1st. UBS Group reduced their price target on shares of Harmony Biosciences from $50.00 to $43.00 and set a “buy” rating on the stock in a research report on Wednesday, October 15th. Oppenheimer reissued an “outperform” rating and set a $62.00 price objective on shares of Harmony Biosciences in a report on Monday, November 24th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Harmony Biosciences in a research note on Wednesday, December 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $45.63.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.